Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin- dependent diabetic men

Journal of Lipid Research

Volumn 37, Issue 8, 1996, Pages 1776-1785

  Gylling, Helena ^a   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

apolipoprotein A I kinetics; apolipoprotein B kinetics; cholesterol precursors; NIDDM; plant sterols; pravastatin plus sitostanol treatment

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CAMPESTEROL; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; PRAVASTATIN; RAPESEED OIL; SITOSTANOL; SITOSTEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ABSORPTION; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTION; ANTICHOLESTEREMIC AGENTS; BLOOD SPECIMEN COLLECTION; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; PATIENT SELECTION; PRAVASTATIN; SITOSTEROLS; TRIGLYCERIDES;

EID: 0029792331     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Grundy, S. M. 1988. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24-33.
2. Miettinen, T. A., P. Puska, H. Gylling, H. Vanhanen, and E. Vartiainen. 1995. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N. Engl. J. Med. 333: 1308-1312.
3. Gylling, H., and T. A. Miettinen. 1994. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia. 37: 773-780.
4. Gylling, H., and T. A. Miettinen. 1995. The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis. 117: 305-308.
5. Harris, M. I. 1991. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care. 14: 366-374.
6. Ginsberg, H. N. 1991. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 14: 839-855.
7. Yoshino, G., T. Kazumi, M. Iwai, M. Matsushita, K. Matsuba, R. Uenoyama, I. Iwatani, and S. Baba. 1989. Long-term treatment of hypercholesterolemic non-insulin-dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis. 75: 67-72.
8. Garg, A., and S. M. Grundy. 1988. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318: 81-86.
9. Miccoli, R., A. Bertolotto, M. G. Giovannitti, I. Tedesco, S. Manfredi, G. Galantini, and R. Navalesi. 1992. Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus and in primary hypercholesterolemia. Curr. Ther. Res. 51: 66-74.
10. Zambon, S., A. Lapolla, G. Sartore, C. Gherardingher, A. Cortella, E. Manzato, G. Crepaldi, and D. Fedele. 1992. Long-term treatment with simvastatin in hypercholesterolemic non-insulin-dependent diabetic patients. Curr. Ther. Res. 52: 221-229.
11. Cassader, M., G. Ruiu, R. Gambino, N. Alemanno, F. Veglia, and G. Pagano. 1993. Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels. Atherosclerosis. 99: 47-53.
12. Miettinen, T. 1979. Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. J. Clin. Invest. 64: 1485-1493.
13. Knuts, L-R., M. Rastas, and P. Haapala. 1991. Micro-Nutrica. Version 1.0. Helsinki: Kansaneläkelaitos.
14. Lipid Research Clinics Program. 1974. Manual of Laboratory Operations. Lipid and Lipoprotein Analysis. National Institutes of Health. DHEW Publication No. (NIH) 75-628. Bethesda, MD. 1:51-59.
15. Gylling, H., H. Vanhanen, and T. A. Miettinen. 1993. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J. Lipid Res. 34: 59-67.
16. Miettinen, T. A. 1982. Gas-liquid chromatographic determination of fecal neutral sterols using a capillary column. Clin. Chim. Acta. 124: 245-248.
17. Crouse, J. R., and S. M. Grundy. 1978. Evaluation of a continuous isotope feeding method for measurement of cholesterol absorption in man. J. Lipid Res. 19: 967-971.
18. Bolin, D. W., R. P. King, and E. W. Klosterman. 1952. A simplified method for the determination of chromic oxide (Cr2O3) when used as an index substance. Science. 116: 634-635.
19. Miettinen, T. A., E. H. Ahrens, Jr., and S. M. Grundy. 1965. Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J. Lipid Res. 6: 411-424.
20. Grundy, S. M., E. H. Ahrens, Jr., and T. A. Miettinen. 1965. Quantitative isolation and gas-liquid chromatographic analysis of total fecal bile acids. J. Lipid Res. 6: 397-410.
21. Czubayko, F., B. Beumers, S. Lammsfuss, D. Lütjohann, and K. von Bergmann. 1991. A simplified micro-method for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J. Lipid Res. 32: 1861-1867.
22. Vega, G. L., H. Gylling, A. V. Nichols, and S. M. Grundy. 1991. Evaluation of a method for study of kinetics of autologous apolipoprotein A-I. J. Lipid Res. 32: 867-875.
23. McFarlane, A. S. 1958. Efficient trace-labeling of proteins with iodine. Nature. 182: 53-57.
24. Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabolism of very low density lipoproteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260: 212-221.
25. Matthews, C. M. E. 1957. The theory of tracer experiments with 131I-labeled plasma proteins. Phys. Med. Biol. 2: 36-53.
26. Miettinen, T. A., R. S. Tilvis, and Y. A. Kesäniemi. 1990. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. EpidemioL 131: 20-31.
27. Vanhanen, H., Y. A. Kesäniemi, and T. A. Miettinen. 1992. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism. 41: 588-595.
28. Vega, G. L., R. M. Krauss, and S. M. Grundy. 1990. Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J. Intern. Med. 227: 81-94.
29. Miettinen, T. A., H. Vanhanen, J-P. Ojala, and M. J. Tikkanen. 1992. Non-cholesterol sterols and fecal elimination of cholesterol during statin and fibrate treatment. Atherosclerosis. 97: S73-S80.
30. Vanhanen, H. 1994. Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolemic patients. Eur. J. Clin. Pharmacol. 47: 169-176.
31. Reihner, E., M. Rudling, D. Stahlberg, L. Berglund, S. Ewerth, I. Björkhem, K. Einarsson, and B. Angelin. 1990. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323: 224-228.
32. Vanhanen, H. T., and T. A. Miettinen. 1995. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 115: 135-146.
33. Goldberg, I. J., S. Holleran, R. Ramakrishnan, M. Adams, R. H. Palmer, R. B. Dell, and D. S. Goodman. 1990. Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J. Clin. Invest. 86: 801-808.
34. Uusitupa, M. I. J., T. A. Miettinen, P. Happonen, T. Ebeling, H. Turtola, E. Voutilainen, and K. Pyörälä. 1992. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guangum. Arterioscler. Thromb. 12: 807-813.
35. Ma, P. T. S., G. Gil, T. C. Sudhof, D. W. Bilheimer, J. L. Goldstein, and M. S. Brown. 1986. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl. Acad. Sci. USA. 83: 83-70-8374.
36. Kervinen, K., M. J. Savolainen, J. I. Heikkilä, and Y. A. Kesäniemi. 1993. Lovastatin enhances hepatic uptake of low density lipoprotein in humans. J. Lipid Res. 34: 1975-1982.
37. Parhofer, K. G., P. H. R. Barrett, J. Dunn, and G. Schonfeld. 1993. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin. Invest. 71: 939-946.
38. Grundy, S. M., and G. L. Vega. 1985. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res. 26: 1464-1475.
39. Gaw, A., C. J. Packard, E. F. Murray, G. M. Lindsay, B. A. Griffin, M. J. Caslake, B. D. Vallance, A. R. Lorimer, and J. Shepherd. 1993. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler. Thromb. 13: 170-189.
40. Arad, Y., R. Ramakrishnan, and H. N. Ginsberg. 1990. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J. Lipid Res. 31: 567-582.
41. Himber, J., B. Missano, M. Rudling, U. Hennes, and H. J. Kempen. 1995. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J. Lipid Res. 36: 1567-1585.
42. Tilly-Kiesi, M. 1991. The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism. 40: 623-628.
43. Kesäniemi, Y. A., and S. M. Grundy. 1984. Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis. 4: 41-48.